Skip to main content

Table 5 Mean geometric IC50 values for each component of AL and ASAQ at D0 (before treatment) versus day of treatment failure among treatment participants

From: In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

Treatment

n

n

P value

IC50 at D0 in nM (IC 95%)

IC50 at DoR in nM (IC 95%)

 

ASAQ

 MDA

188

33

–

19.80 (17.83–21.99)

24.94 (20.68–30.08)

0.94

 DHA

190

34

–

0.85 (0.76–0.95)

0.66 (0.47–0.93)

0.96

AL

 DHA

191

54

–

0.8 (0.72–0.90)

0.67 (0.54–0.83)

0.43

 LUM

192

53

–

24.13 (20.45–28.46)

37.07 (28.37–48.44)

0.05

  1. nM nanomolar, DoR day of recurrent parasitaemia, ASAQ amodiaqine–artesunate, AL artemether lumefantrine, MDA monodesethylamodiaquine, DHA dihydroartermisinin, LUM lumefantrine
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us